<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172963</url>
  </required_header>
  <id_info>
    <org_study_id>DSCHC001</org_study_id>
    <nct_id>NCT02172963</nct_id>
  </id_info>
  <brief_title>A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy using placenta derived
      decidual stromal cell therapy for hemorrhagic cystitis after allogeneic hematopoietic cell
      transplantation. It is hypothesized that the decidual stromal cell therapy is safe to infuse
      and that they have a positive clinical effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with grade 2-4 hemorrhagic cystitis will receive decidual stromal cell therapy at
      approximately 1-2x10^6 cells/kg once or at weekly intervals dependent on clinical effect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response at day 28 after onset of hemorrhagic cystitis</measure>
    <time_frame>28 days after inclusion</time_frame>
    <description>Disappearance of macroscopic hematuria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Actuarial survival at one year after onset of hemorrhagic cystitis</measure>
    <time_frame>One year after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disappearance of pain or urges</measure>
    <time_frame>Up to 6 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disappearance of microscopic hematuria</measure>
    <time_frame>Up to 84 days after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>Up to one year after inclusion</time_frame>
    <description>All mortality except for relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe infections</measure>
    <time_frame>Up to one year after inclusion</time_frame>
    <description>Incidence of severe bacterial, viral or fungal infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>Up to one year after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hemorrhagic Cystitis</condition>
  <arm_group>
    <arm_group_label>Decidual Stromal Cell therapy for Hemorrhagic Cystitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Decidual Stromal Cell therapy</intervention_name>
    <description>Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10^6 cells/kg.</description>
    <arm_group_label>Decidual Stromal Cell therapy for Hemorrhagic Cystitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemorrhagic cystitis grade 2-4

        Exclusion Criteria:

          -  Urinary urge without macroscopic hematuria or clots
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olle Ringdén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Olle Ringdén</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Decidual Stromal Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

